plasminogen
美 [plæz'm?n?d??n] 
英 [plæz'm?n?d??n]
- n.纖維蛋白溶酶原；血纖維蛋的溶酶原；前纖維蛋白溶酶；纖維蛋白溶解原
- 網絡纖溶酶原；胞漿素原；血纖維蛋白溶酶原
英漢解釋
英英解釋
例句
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
結論：糖尿病腎病患者存在血漿纖溶酶原激活物及其抑制物系統失衡。
abstract: Objective To investigate the plasminogen activator inhibitor changes in patients with diabetic nephropathy.
目的：探討糖尿病腎病患者血漿纖溶酶原激活物抑制物的變化。
Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated.
臨床上有指征時也可應用重組組織型纖溶酶原激活劑。
Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.
急性缺血性卒中患應用重組組織纖溶酶原激活劑治療的效用成本：一項系統性回顧
The abnormal activity of tissue-type plasminogen activator(t-PA) is the most risk factor of prethrombotic state of cardiovascular diseases.
組織型纖溶酶原激活物（tPA）活性異常是心血管疾病血栓前狀態的最危險因素。
Plasminogen has been immobilized onto a segmented polyurethane containing amino groups, using glutaraldehyde as coupling agent.
纖溶酶原已被固定在一個分割的含氨基酸組，用偶聯劑戊二醛聚氨酯。
abstract: Objective: To discuss the clinical value of detecting blood plasminogen activator and inhibitor in cancer patients.
目的：探討惡性腫瘤患者血液纖溶酶原激活劑與抑制劑檢測的臨床應用價值。
THE EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN ORAL SQUAMOUS CELL CARCINOMA.
尿激酶受體在口腔鱗癌中的表達。
HMGB1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.
HMGB1與纖維蛋白酶原、基質金屬蛋白酶的活化、細胞骨架重組等有關。
A drug called tissue plasminogen activator -- tPA -- dissolves clots and restores blood flow.
而一種稱為組織纖維蛋白溶酶原激活物（tPA）的藥物可以溶解血塊，并恢復血液流通。
The high-phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.
高酚早餐組另一血栓促進因子——纖維蛋白溶酶原活化抑制因子-1的活性也呈現顯著降低。
Reteplase is a part of human tissue-type plasminogen. It is expressed in Escherichia Coli cells.
瑞替普酶是人類組織型纖溶酶原激活物的一部份，在大腸桿菌中合成。
Plasminogen activator inhibitor-1(PAI-1)is the main regulator of the fibrinolytic system.
血漿纖溶酶原激活物抑制劑（PAI）-1是纖溶系統的主要調控因子。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纖溶酶原激活物抑制劑1（PAI-1）是一種單鏈糖蛋白，起抑制纖溶活性的作用。
Because of extensive purpura fulminans with skin necrosis recombinant tissue plasminogen activator (rt-PA) was used.
由于廣泛的暴發性紫癜皮膚壞死與重組組織型纖溶酶原激活劑（酶原激活劑）的使用。
NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在兩個試驗中，在組織纖維蛋白溶酶原激活劑使用前，都先用NIHSS評分。
Objective: To study the risk factor of Triglyceride and Plasminogen Activity on abnormal in patients with Cerbral Infarction.
前言：目的：探討腦梗塞患者血高甘油三酯與纖溶系統異常的危險因素。
Expression and its significance of urokinase-type plasminogen activator system in a nasopharyngeal carcinoma cell line and two sub-lines
尿激酶型纖溶酶原激活劑系統在鼻咽癌細胞系及其兩個克隆株中的表達和意義
Study of Activity of Plasminogen Activator and Plasminogen Activator Inhibitor in Experimental Diabetic Rats with Cerebral Ischemia
實驗性糖尿病大鼠腦缺血纖溶酶原激活物和纖溶酶原激活物抑制劑活性測定
Effect of tissue-typed plasminogen activator on the adhesion of platelets on the surface of biomaterials
組織型纖溶酶原激活因子對生物材料表面血小板黏附的影響
Effects of Chemical Modification on the Fibrinolytic Activity and Half-Life of Recombinant Tissue-Type Plasminogen Activator
化學修飾對組織型纖溶酶原激活劑的纖溶活性和體內半衰期的影響
Dynamic Changes and Significance of Plasma Urokinase-Type Plasminogen Activator and its Receptor in Rats after Pulmonary Thromboembolism
肺血栓栓塞癥大鼠血漿尿激酶型纖溶酶原激活物及其受體的動態變化及其意義
Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator
一種導向性溶栓劑的基因構建及其在大腸桿菌中的表達
Polymorphism of plasminogen activator inhibitor-1 gene in the children of elderly patients with type 2 diabetes mellitus
老年2型糖尿病患者子女纖溶酶原激活物抑制物1基因的多態性
Intravenous thrombolysis therapies in acute myocardial infarction with the reconstructive tissue plasminogen activator in prehospital care
急性心肌梗死院前應用重組組織型纖溶酶原激活劑溶栓研究
Expression of urokinase-type plasminogen activator receptor and its significance in laryngeal squamous cell carcinoma
尿激酶型纖溶酶原激活劑受體在喉鱗癌中的表達及意義
The relation between the expression of urokinase-type plasminogen activator receptor and clinical pathologic grade in human brain glioma
人腦膠質瘤中尿激酶型纖溶酶原激活物受體的表達與臨床病理分級的關系
Clinical Thrombolytic Trial of A New Type of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction
一種新的人組織纖溶酶原激活劑對急性心肌梗死的溶栓效果
Study on the Expression of Urokinase-type Plasminogen Activator Receptor in Thrombotic Patients and its Clinical Implications
尿激酶受體在血栓性疾病中的表達及臨床意義
Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis
骨關節炎滑膜中尿激酶型纖溶酶原激活物及其受體蛋白的表達
Expression of Urokinase-type Plasminogen Activator Receptor in Epithelial Ovarian Cancer and its Significance
尿激酶型纖溶酶原激活物受體在上皮性卵巢癌中的表達及其意義
Clinical Significance of Measurement of Plasma Urokinase Type Plasminogen Activator and its Receptor in Cancer Patients
癌癥患者尿激酶型纖溶酶原激活物及其受體檢測的臨床意義
Discussion for the Problems in Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction
急性腦梗死靜脈溶栓治療的難點與對策
Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx
尿激酶型纖溶酶原激活劑及其抑制劑在喉癌患者預后中的價值
Correlation of the expression of plasminogen activation system with the occurrence, development and prognosis of ovarian cancer
卵巢癌發生、進展及預后與纖溶酶原激活系統表達的關系
Detection of Plasminogen activator and thrombomodulin in lung cancer patients and its clinical significance
肺癌患者纖溶酶原激活物和血栓調節蛋白檢測分析
Relationship between the Changes of Activity of Tissue-Type Plasminogen Activator on Brains and Cerebral Edema in Asphyxia Status of Mice
窒息鼠腦組織型纖溶酶原激活物活性變化與腦水腫的關系
The relationship between the behavior types and plasminogen activation system in patients with coronary heart disease
冠心病患者行為類型與纖溶激活系統改變的相關性研究
The change of plasma urokinase-type plasminogen activator and its receptor in patients with intracerebral hemorrhage
腦出血患者尿激酶型纖溶酶原激活物及其受體的變化
Expression of urokinase - type plasminogen activator and its receptor in plasma of patients with cerebral infarction
急性腦梗死患者血漿尿激酶型纖溶酶原激活物及其受體的表達
